Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— 8.88 10.35 24.51

+8 more quarters

P/S ratio
— 0.63 0.75 0.84
P/FCF ratio
— 9.06 9.85 14.04
P/Operating CF
— 42.39 13.70 17.58
P/B ratio
— 0.59 0.74 0.78
EV/Sales
— 1.84 1.91 2.10
EV/EBITDA
— 8.23 8.51 9.61
EV/FCF
— 26.37 25.24 35.25
Current Ratio
2.37 2.47 2.51 2.48
Net Debt/EBITDA
0.00 25.10 22.27 19.13
Debt/Equity
1.17 1.23 1.27 1.28
Earnings Yield
— 11.26% 9.66% 4.08%
Free Cash Flow Yield
— 11.04% 10.15% 7.12%
Free Cash Flow per Share
0.00 0.00 0.48 0.00
Book value per Share
0.00 0.00 12.64 0.00
Free Cash Flow
128.91 23.41 327.96 259.44
EV/EBIT
— 11.21 11.59 11.94
Other line items

Show all line items

Columns are period end dates